Before You Inject Peptides, Watch This - 16 Years of Clinical Reality

The FDA just voted to legalize six peptides for compounding. The pharmaceutical industry is fighting back hard. And somewhere in the middle of all of this are the practitioners who have been using these compounds quietly and effectively for almost two decades. This is their story.

Dr. Alice: The Person Behind Stark's Peptide Protocols

Dr. Alice — Dr. Alice Nin — has been practicing for a decade and has been guiding Stark's clinical protocols, including our peptide programs, longer than most people have even known what a peptide is. She was first exposed to peptides 16 years ago, introduced to a compound called Epitalon by her mentor, a peptide innovator named Peter Rouse. At the time, he was one of the only people with serious clinical knowledge of what peptides were and why they worked.

When she brought peptide research into medical school in 2015, her instructors were confused and dismissive. She briefly assumed they were fringe. Then she was invited to a peptide conference — and the field's trajectory became clear. The next decade would change everything about how peptides are understood and used in clinical medicine.

From Melanotan to Semaglutide: How the Field Evolved

The second peptide Dr. Alice encountered was melanotan — a compound known for triggering tanning, but whose more significant clinical side effect turned out to be dramatically elevated libido, particularly in women. Melanotan and its successor PT-141 are both clinically indicated for hypoactive sexual desire disorder. The downside: existing moles darken substantially, sometimes permanently. A meaningful tradeoff for some patients.

From those early compounds, the peptide world evolved rapidly toward GLP-1s. Dr. Alice first encountered semaglutide through a type 1 diabetic patient prescribed Ozempic around 2016–2018 — before most people had heard of it. She went from never having heard of it to watching it become the most-discussed pharmaceutical intervention in the world. The clinical reality she's observed in that time is more nuanced than most of what you'll read online.

The Lean Mass Problem — What the Ads Don't Show

Stark's position on GLP-1s is grounded in DEXA data — the gold standard for measuring body composition. When Stark students on GLP-1 protocols get their scans, what the team consistently sees is a loss of 10 pounds of lean muscle mass. That is years of training. Extremely difficult to replace, particularly for women and for anyone over 40.

This is the number that nobody puts in GLP-1 advertisements. And it's why at Stark, GLP-1 use is never an isolated decision — it's embedded in a coordinated protocol that includes TRT where appropriate, high protein intake, strength training programming, sleep quality, and recovery monitoring. When those elements are in place, the outcomes can be exceptional. When they're not, the trade-off is severe.

BPC-157, TB-500, and the Honest Landscape

BPC-157 is one of the most talked-about peptides right now — and the clinical reality is genuinely mixed. Dr. Alice has seen excellent results: a student injured out of state received an overnight shipment of BPC-157, TB-500, collagen, and vitamin C, and his out-of-state doctors reported remarkable recovery progress. She's also had cases where there was no measurable benefit at all. Injectable, oral, and liposomal formulations behave differently. Individual response varies.

The honest framework: peptides are not a guarantee. They're not a scam. They're a frontier that requires individual clinical assessment, careful monitoring, and coordination with the rest of a person's health program. The FDA's move to recommend six peptides for compounding represents a significant step toward bringing that frontier under clinical accountability — which is where it belongs.